Abstract
Abstract not available.
Highlights
◾ In this phase 2 study, patients aged 12 years and older were randomized (2:2:1:1) to receive tazarotene 0.045% lotion, tazarotene 0.1% cream (Tazorac), lotion vehicle, or cream vehicle Participants must have had a score of 3 or 4 on the Evaluator’s Global Severity Score (EGSS) at the screening and baseline visit In this study, CeraVe® hydrating cleanser and CeraVe® moisturizing lotion (L’Oreal, NY) were provided as needed for optimal moisturization/cleaning of the skin
Mean absolute change in inflammatory and noninflammatory lesion counts from baseline to week 12
◾ There were no significant differences between the sexes on inflammatory/noninflammatory lesion counts or treatment success at week 12, regardless of treatment with tazarotene 0.045% lotion or tazarotene 0.1% cream
Summary
◾ In this phase 2 study, patients aged 12 years and older were randomized (2:2:1:1) to receive tazarotene 0.045% lotion, tazarotene 0.1% cream (Tazorac), lotion vehicle, or cream vehicle Participants must have had a score of 3 (moderate) or 4 (severe) on the Evaluator’s Global Severity Score (EGSS) at the screening and baseline visit In this study, CeraVe® hydrating cleanser and CeraVe® moisturizing lotion (L’Oreal, NY) were provided as needed for optimal moisturization/cleaning of the skin. ◾ A post hoc analysis was conducted in female and male patients, based on the following co-primary efficacy endpoints of the clinical trial: Mean absolute change in inflammatory and noninflammatory lesion counts from baseline to week 12 Treatment success, defined as percentage of patients achieving ≥2-grade reduction from baseline to week 12 in EGSS and a score of clear (0) or almost clear (1)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
